Rebiotix is working closely with the U.S. FDA as it conducts an advanced clinical research program

Clinical Trials

Rebiotix is conducting an advanced clinical program assessing its Microbiota Restoration Therapy (MRT).

Lead product RBX2660 is currently under study for the prevention of recurrent Clostridium difficile (C. diff.) infection.

For currently enrolling clinical trials, go to and search for Rebiotix.

Important milestones include:

  • PUNCH CD study: Phase 2 multicenter, open-label study. Reported in October 2014.
  • PUNCH CD2: Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled study of a microbiota-based drug. Enrollment completed Q3 2015.

Special FDA designations for RBX2660:

  • Fast Track – May 2013
  • Orphan Drug – March 2014
  • Breakthrough Therapy – October 2015